Sign In
Buy BLE
$10.54
+0 (+0%)
At Close: May 05, 2026
Retail Analytics Market Size, Revenue, End Users And Forecast Till —…—6| Fortune Business ...
12:00am, Tuesday, 11'th Feb 2020bluebird bio Announces Upcoming Investor Events
01:00pm, Wednesday, 05'th Feb 2020
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will present at the following upcoming investor conferences: 9th Annual SVB Lee
BlackRock Municipal Income Trust II -- Moody's announces completion of a periodic review of ratings of BlackRock Municipal Income Trust II
03:14pm, Wednesday, 29'th Jan 2020
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of BlackRock Municipal Income Trust II and other ratings that are associated with the same analytical unit. The re
Municipal Bonds: 4 Ways To Stay Flexible In 2020
12:46pm, Wednesday, 29'th Jan 2020
The seemingly insatiable appetite for municipal bonds easily absorbed an uptick in gross new issuance in 2019. With yields likely to remain low, we expect conti
Municipal Bond Perspective: Approach High Yield With Caution In 2020
03:30am, Wednesday, 29'th Jan 2020
The municipal bond market presents a number of unique features and characteristics that set it apart from traditional asset classes. Only around 10% of the muni
Could The Tail Wag The Dog?
06:09am, Friday, 24'th Jan 2020
Every once in a while, Treasury yields can take their cue from an overseas sovereign debt, such as German bunds. The 10-year bund recorded an all-time low of -0
Funding Your Wealth
03:33pm, Wednesday, 22'nd Jan 2020
With the 3 month bill at 1.54%, the 2 year Treasury at 1.53% and the 10 year Treasury at 1.77% it's obvious we continue to live in a Borrower's Paradise. Lower
2019: Bonds Roar Back
09:12am, Tuesday, 14'th Jan 2020
2019 saw bond yields turn around from their climb in 2018 and move lower. The 10-year Treasury started the year at 2.70% and ended the year at 1.90%, after maki
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced the launch in Germany of ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene), a one-time gene therapy for
bluebird bio Announces Investor Events in January
09:05pm, Thursday, 19'th Dec 2019
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will present at the following upcoming investor conferences in January: Goldman
Bluebird Bio Stock Is Rising on Promising Cancer-Drug Data
02:16pm, Monday, 09'th Dec 2019
Shares took off Monday morning after the company reported data at a medical conference over the weekend that relieved investor anxiety over the company’s experimental cancer drug ide-cel.
bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin™ Gene Therapy for Sickle Cell Disease (SCD) at ASH Annual Meeting
